Optimizerx CORP Form 4 insider transactions

OptimizeRx's General Counsel and CCO, Marion Odence-Ford, was granted stock options and restricted stock units on December 23, 2024.

OptimizeRx's Chief Product Officer, Doug Besch, acquired 41,408 restricted stock units and 77,742 stock options on December 23, 2024.

OptimizeRx Corp's General Counsel and CCO, Marion Odence-Ford, reported the acquisition of 3,927 shares through restricted stock unit vesting and the disposition of 1,153 shares for tax obligations.

OptimizeRx's Chief Commercial Officer, Stephen L. Silvestro, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

OptimizeRx Corp's Chief Product Officer, Doug Besch, reports the acquisition of 1,964 shares through restricted stock units and the disposition of 577 shares for tax obligations.

OptimizeRx CFO/COO Edward Stelmakh reported the acquisition of 5,237 shares of common stock through the vesting of restricted stock units and the disposition of 1,316 shares to cover tax obligations.

OptimizeRx CEO William Febbo purchased 20,000 shares of company stock at an average price of $5.011 per share on December 12, 2024.

Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports exercising stock options and disposing of shares to cover tax obligations.

Theresa Greco, Chief Commercial Officer of OptimizeRx Corp, disposed of 1,693 shares of common stock on November 1, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, reports the vesting and subsequent tax withholding of shares.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, filed a Form 4 detailing the acquisition and disposition of common stock and restricted stock units.

Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting of restricted stock units and subsequent tax withholding.

Doug Besch, Chief Product Officer of OptimizeRx Corp, reports the vesting and subsequent disposal of shares to cover tax obligations.

Brian Clark McCarthy, Chief Revenue Officer of OptimizeRx Corp, reports acquisition of stock options and restricted stock units.

OptimizeRx CEO William Febbo reports the vesting of restricted stock units and subsequent tax withholding.

Director Patrick D. Spangler reports acquisition and disposal of OptimizeRx Corp stock, including the vesting of restricted stock units.

Director Vos Ellen O'Connor reports acquisition and disposal of OptimizeRx Corp (OPRX) common stock and restricted stock units.

Director Gregory D. Wasson reports acquisition and disposal of OptimizeRx Corp (OPRX) common stock and restricted stock units.

Director Halas Gus D of OptimizeRx Corp. acquired 10,061 shares of common stock on June 5, 2024, through the vesting of restricted stock units.

Director Cathy Klema acquired 6,643 shares of OptimizeRx Corp through restricted stock units, which vest on the earlier of the first anniversary of the grant date or the next annual meeting.

Director James Paul Lang reports acquisition and disposal of OptimizeRx Corp (OPRX) common stock and restricted stock units.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting of restricted stock units and subsequent tax withholding.

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, files an amended Form 4 to correct an understatement of beneficially owned shares and an overstatement of shares withheld for tax obligations.

Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, files an amended Form 4 to correct the grant date of common stock and adjust the number of beneficially owned shares.

OptimizeRx CEO William Febbo was granted 15,000 restricted stock units that will vest on February 15, 2025.

Chief Product Officer Doug Besch acquired 4,000 restricted stock units of OptimizeRx Corp on February 15, 2024, which will vest on February 15, 2025.

Marion Odence-Ford, General Counsel and CCO of OptimizeRx Corp, reports the acquisition of restricted stock units.

Edward Stelmakh, CFO/COO of OptimizeRx Corp, reports the acquisition and disposal of common stock and grant of restricted stock units.

Stephen Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the acquisition of 7,750 restricted stock units.